![Stevens‐Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System - Borrelli - 2018 - Epilepsia - Wiley Online Library Stevens‐Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System - Borrelli - 2018 - Epilepsia - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/a13a6592-9f1f-4d21-9e4e-734a28378d82/epi14591-fig-0001-m.jpg)
Stevens‐Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System - Borrelli - 2018 - Epilepsia - Wiley Online Library
![Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States | Business Wire Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States | Business Wire](https://mms.businesswire.com/media/20210114006024/en/739014/22/teva_RGB_JPEG.jpg)
Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States | Business Wire
![Stevens‐Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System - Borrelli - 2018 - Epilepsia - Wiley Online Library Stevens‐Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System - Borrelli - 2018 - Epilepsia - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/8ddfb4e9-daa8-4270-bc30-e9a9d30f259e/epi14591-fig-0002-m.jpg)
Stevens‐Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System - Borrelli - 2018 - Epilepsia - Wiley Online Library
![Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. - Abstract - Europe PMC Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5710324/bin/jamaneurol-74-919-g001.jpg)
Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. - Abstract - Europe PMC
![Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. - Abstract - Europe PMC Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5710324/bin/jamaneurol-74-919-g002.jpg)
Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. - Abstract - Europe PMC
![Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial - The Lancet Neurology Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2e3cbd4e-6095-448f-9448-b8a3500cabab/gr1.gif)